

Experiment Number: 20209 - 04

**P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH
AVERAGE SEVERITY GRADES[b]**

Date Report Requested: 09/10/2014

Test Type: CHRONIC

Pentabromodiphenyl oxide (technical) (DE 71)

Time Report Requested: 08:48:44

Route: GAVAGE

CAS Number: 32534-81-9

First Dose M/F: 02/25/08 / 02/25/08

Species/Strain: MICE/B6C3F1

Lab: SRI

F1_Rev.1_M3

NTP Study Number: C20209
Lock Date: 08/31/2011
Cage Range: ALL
Date Range: ALL
Reasons For Removal: ALL
Removal Date Range: ALL
Treatment Groups: Include ALL
Study Gender: Both
TDMSE Version: 3.0.2.2_002
PWG Approval Date: NONE

Test Type: CHRONIC

Pentabromodiphenyl oxide (technical) (DE 71)

Time Report Requested: 08:48:44

Route: GAVAGE

CAS Number: 32534-81-9

First Dose M/F: 02/25/08 / 02/25/08

Species/Strain: MICE/B6C3F1

Lab: SRI

B6C3F1 MICE MALE	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
------------------	---------	---------	----------	-----------

Disposition Summary

Animals Initially In Study	50	50	50	50
Early Deaths				
Dosing Accident	1			2
Moribund Sacrifice	15	7	14	36
Natural Death	5	10	5	12
Survivors				
Terminal Sacrifice	29	33	31	
Animals Examined Microscopically	50	50	50	50

ALIMENTARY SYSTEM

Esophagus	(50)	(50)	(50)	(50)
Foreign Body				1 [4.0]
Inflammation, Acute	1 [2.0]			2 [1.5]
Inflammation, Chronic		1 [1.0]		
Mineralization	1 [1.0]			
Necrosis	1 [2.0]			2 [2.5]
Muscularis, Degeneration		2 [1.0]	2 [1.5]	
Gallbladder	(43)	(42)	(41)	(31)
Cyst			1 [2.0]	
Intestine Large, Cecum	(46)	(43)	(45)	(45)
Lymphoid Tissue, Necrosis	1 [3.0]			
Intestine Large, Colon	(48)	(44)	(46)	(46)
Intestine Large, Rectum	(48)	(46)	(46)	(46)
Serosa, Fibrosis		1 [2.0]		
Intestine Small, Duodenum	(46)	(43)	(47)	(44)
Infiltration Cellular, Plasma Cell			1 [1.0]	
Inflammation			1 [2.0]	
Intestine Small, Ileum	(45)	(41)	(44)	(43)
Intestine Small, Jejunum	(46)	(42)	(44)	(46)
Peyer's Patch, Hyperplasia		1 [2.0]		
Serosa, Fibrosis				1 [2.0]
Liver	(50)	(50)	(50)	(50)
Angiectasis			1 [1.0]	

a - Number of animals examined microscopically at site and number of animals with lesion

b-Average severity grade(1-minimal;2-mild;3-moderate;4-marked)

Test Type: CHRONIC

Pentabromodiphenyl oxide (technical) (DE 71)

Time Report Requested: 08:48:44

Route: GAVAGE

CAS Number: 32534-81-9

First Dose M/F: 02/25/08 / 02/25/08

Species/Strain: MICE/B6C3F1

Lab: SRI

B6C3F1 MICE MALE	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Basophilic Focus	6	2		5
Basophilic Focus, Multiple		1	1	
Clear Cell Focus	10	6	17	7
Clear Cell Focus, Multiple		7	3	
Congestion		1 [1.0]		
Depletion Glycogen	1 [2.0]	1 [2.0]		
Eosinophilic Focus	14	12	4	10
Eosinophilic Focus, Multiple	1	10	6	1
Fatty Change	17 [2.1]	25 [1.3]	17 [2.0]	5 [1.6]
Hematopoietic Cell Proliferation	10 [1.2]	5 [1.0]	1 [1.0]	3 [1.0]
Hemorrhage	3 [2.0]	1 [1.0]	1 [1.0]	2 [1.5]
Inflammation, Chronic	13 [1.2]	19 [1.2]	22 [1.3]	12 [1.3]
Mineralization	1 [1.0]			
Mixed Cell Focus	2	4		1
Mixed Cell Focus, Multiple		1		
Necrosis, Focal	2 [3.0]	2 [1.0]	16 [1.1]	2 [2.5]
Tension Lipidosis	1 [1.0]			
Bile Duct, Cyst	1			
Centrilobular, Hepatocyte, Hypertrophy		28 [1.4]	46 [3.7]	48 [3.9]
Hepatocyte, Mitotic Alteration		1 [1.0]		
Hepatocyte, Necrosis				1 [2.0]
Kupffer Cell, Pigmentation	5 [1.0]	15 [1.3]	33 [1.6]	25 [1.3]
Mesentery	(12)	(3)	(9)	(5)
Hemorrhage	1 [2.0]			
Inflammation, Chronic	1 [2.0]			1 [1.0]
Artery, Inflammation, Chronic Active			2 [2.5]	2 [3.0]
Artery, Thrombosis	1 [2.0]			
Fat, Necrosis	8 [2.0]	3 [2.3]	6 [2.0]	2 [2.0]
Pancreas	(50)	(50)	(50)	(50)
Atrophy	10 [1.5]	14 [1.4]	7 [1.7]	
Cyst	1 [2.0]	4 [2.0]		
Degeneration				1 [3.0]
Hemorrhage				1 [2.0]
Hypertrophy, Focal	1 [2.0]			
Inflammation, Granulomatous, Focal		1 [3.0]		
Inflammation, Acute		1 [2.0]		

a - Number of animals examined microscopically at site and number of animals with lesion

b-Average severity grade(1-minimal;2-mild;3-moderate;4-marked)

Test Type: CHRONIC

Pentabromodiphenyl oxide (technical) (DE 71)

Time Report Requested: 08:48:44

Route: GAVAGE

CAS Number: 32534-81-9

First Dose M/F: 02/25/08 / 02/25/08

Species/Strain: MICE/B6C3F1

Lab: SRI

B6C3F1 MICE MALE	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Inflammation, Chronic	12 [1.1]	17 [1.1]	19 [1.2]	8 [1.0]
Inflammation, Chronic Active	2 [2.0]			
Mineralization		2 [2.0]		
Necrosis		2 [2.0]		
Acinus, Hyperplasia, Focal			1 [1.0]	
Artery, Inflammation, Chronic Active		1 [2.0]		
Artery, Mineralization		1 [1.0]		
Artery, Necrosis		1 [2.0]		
Salivary Glands	(50)	(50)	(50)	(50)
Atrophy	2 [2.0]			
Cyst	1 [2.0]			
Hyperplasia, Lymphoid				1 [1.0]
Infiltration Cellular, Mononuclear Cell	31 [1.0]	38 [1.1]	30 [1.1]	21 [1.0]
Inflammation, Granulomatous	1 [2.0]			
Inflammation, Acute		1 [2.0]		
Mineralization		5 [1.2]	4 [1.0]	1 [1.0]
Necrosis		1 [1.0]		
Vacuolization Cytoplasmic, Macrovesicular		1 [2.0]		
Stomach, Forestomach	(50)	(50)	(50)	(50)
Cyst		1		
Edema			2 [2.0]	
Erosion	4 [2.5]	5 [2.2]	9 [2.4]	3 [3.0]
Fibrosis	2 [1.5]			
Foreign Body			2	
Inflammation	18 [1.7]	18 [1.6]	34 [1.7]	19 [1.7]
Mineralization	1 [1.0]			1 [2.0]
Necrosis	1 [2.0]		1 [3.0]	
Ulcer	9 [2.3]	8 [1.9]	14 [2.1]	11 [2.5]
Epithelium, Hyperplasia	26 [2.1]	19 [2.2]	40 [2.4]	29 [2.9]
Serosa, Fibrosis			1 [2.0]	
Stomach, Glandular	(50)	(48)	(48)	(50)
Dilatation			1 [2.0]	
Edema			1 [1.0]	
Erosion			1 [2.0]	2 [2.5]
Fibrosis		1 [1.0]		
Hemorrhage				1 [2.0]

a - Number of animals examined microscopically at site and number of animals with lesion

b-Average severity grade(1-minimal;2-mild;3-moderate;4-marked)

Test Type: CHRONIC

Pentabromodiphenyl oxide (technical) (DE 71)

Time Report Requested: 08:48:44

Route: GAVAGE

CAS Number: 32534-81-9

First Dose M/F: 02/25/08 / 02/25/08

Species/Strain: MICE/B6C3F1

Lab: SRI

B6C3F1 MICE MALE	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Inflammation	1 [1.0]	1 [1.0]	2 [1.5]	
Inflammation, Acute	1 [1.0]	1 [1.0]		
Mineralization	4 [2.0]	5 [1.6]	6 [1.5]	2 [1.5]
Necrosis			1 [2.0]	
Ulcer	1 [2.0]		2 [1.5]	1 [4.0]
Glands, Ectasia, Focal		1 [1.0]	2 [1.0]	
Serosa, Fibrosis			1 [2.0]	
Tongue	(0)	(0)	(0)	(1)
Angiectasis				1 [1.0]
Tooth	(2)	(1)	(0)	(1)
Inflammation, Acute	1 [2.0]			1 [3.0]
Inflammation, Chronic Active	1 [3.0]			
Malformation		1 [4.0]		
Necrosis	1 [2.0]			

CARDIOVASCULAR SYSTEM

Blood Vessel	(50)	(49)	(50)	(50)
Heart	(50)	(50)	(50)	(50)
Cardiomyopathy	8 [1.0]	10 [1.1]	7 [1.1]	1 [1.0]
Inflammation, Acute		1 [2.0]		
Mineralization	1 [2.0]		5 [1.4]	5 [1.8]
Thrombosis		1 [4.0]		
Artery, Inflammation, Chronic Active	1 [2.0]			
Artery, Mineralization			1 [1.0]	

ENDOCRINE SYSTEM

Adrenal Cortex	(50)	(50)	(49)	(48)
Accessory Adrenal Cortical Nodule	2 [1.5]	2 [2.0]	7 [2.0]	1 [2.0]
Degeneration, Fatty	1 [1.0]		1 [1.0]	2 [1.0]
Hyperplasia			1 [2.0]	
Hypertrophy, Focal	10 [1.4]	10 [1.2]	5 [2.2]	3 [2.0]
Hypertrophy, Diffuse	1 [1.0]		3 [1.3]	20 [1.4]
Vacuolization Cytoplasmic	1 [1.0]		1 [1.0]	1 [2.0]

a - Number of animals examined microscopically at site and number of animals with lesion

b-Average severity grade(1-minimal;2-mild;3-moderate;4-marked)

Test Type: CHRONIC

Pentabromodiphenyl oxide (technical) (DE 71)

Time Report Requested: 08:48:44

Route: GAVAGE

CAS Number: 32534-81-9

First Dose M/F: 02/25/08 / 02/25/08

Species/Strain: MICE/B6C3F1

Lab: SRI

B6C3F1 MICE MALE	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Capsule, Fibrosis				1 [2.0]
Capsule, Hemorrhage				1 [2.0]
Capsule, Hyperplasia	42 [1.7]	41 [1.8]	47 [1.7]	41 [1.6]
Adrenal Medulla	(50)	(50)	(50)	(48)
Hyperplasia		1 [2.0]		1 [1.0]
Islets, Pancreatic	(50)	(50)	(50)	(50)
Hyperplasia	32 [1.3]	25 [1.6]	21 [1.5]	6 [1.0]
Parathyroid Gland	(48)	(43)	(49)	(44)
Cyst	3 [2.0]	1 [2.0]	5 [2.0]	
Pituitary Gland	(47)	(43)	(43)	(44)
Pars Distalis, Angiectasis	1 [3.0]			
Pars Distalis, Cyst	2 [2.0]	2 [2.0]		1 [2.0]
Pars Distalis, Hyperplasia, Focal		1 [2.0]	4 [1.3]	1 [2.0]
Thyroid Gland	(50)	(49)	(50)	(49)
Hypertrophy		1 [1.0]		
Mineralization	1 [1.0]			
C-cell, Hyperplasia			1 [2.0]	
Follicle, Cyst			1	1
Follicle, Degeneration	21 [1.6]	19 [1.6]	12 [1.4]	6 [1.3]
Follicle, Degeneration, Focal		1 [2.0]		
Follicle, Hypertrophy	25 [1.2]	35 [1.4]	41 [2.0]	45 [2.4]

GENERAL BODY SYSTEM

Tissue NOS	(2)	(1)	(0)	(1)
Abdominal, Fibrosis		1 [2.0]		
Fat, Necrosis		1 [2.0]		

GENITAL SYSTEM

Coagulating Gland	(1)	(0)	(1)	(0)
Cyst	1 [4.0]			
Epididymis	(50)	(50)	(50)	(50)
Fibrosis				1 [2.0]
Granuloma Sperm	1 [3.0]		1 [4.0]	

a - Number of animals examined microscopically at site and number of animals with lesion

b-Average severity grade(1-minimal;2-mild;3-moderate;4-marked)

Test Type: CHRONIC

Pentabromodiphenyl oxide (technical) (DE 71)

Time Report Requested: 08:48:44

Route: GAVAGE

CAS Number: 32534-81-9

First Dose M/F: 02/25/08 / 02/25/08

Species/Strain: MICE/B6C3F1

Lab: SRI

B6C3F1 MICE MALE	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Inflammation, Granulomatous	1 [2.0]			
Inflammation, Chronic	21 [1.1]	28 [1.2]	24 [1.3]	7 [1.1]
Inflammation, Chronic Active	1 [3.0]			
Necrosis	1 [2.0]			
Artery, Inflammation	1 [2.0]			
Penis	(1)	(0)	(1)	(0)
Concretion	1 [4.0]			
Inflammation, Acute	1 [2.0]			
Preputial Gland	(50)	(50)	(50)	(50)
Cyst	9 [2.2]	16 [2.0]	14 [2.1]	3 [1.3]
Ectasia		1 [3.0]		
Fibrosis		1 [3.0]		
Inflammation, Acute	2 [2.0]			1 [2.0]
Inflammation, Chronic	24 [1.6]	28 [1.6]	25 [1.7]	5 [1.2]
Inflammation, Chronic Active	1 [2.0]	1 [1.0]	3 [2.0]	
Necrosis			1 [1.0]	
Prostate	(50)	(50)	(50)	(50)
Atrophy			1 [2.0]	
Fibrosis		1 [2.0]		
Inflammation, Granulomatous				1 [2.0]
Inflammation, Acute	4 [3.0]	2 [2.5]	1 [1.0]	
Inflammation, Chronic	27 [1.1]	33 [1.3]	30 [1.2]	15 [1.0]
Inflammation, Chronic Active		1 [4.0]		
Necrosis		1 [2.0]		
Epithelium, Hyperplasia	3 [1.3]		1 [1.0]	
Seminal Vesicle	(50)	(50)	(49)	(49)
Atrophy			1 [2.0]	
Dilatation		1 [4.0]		
Hemorrhage		1 [2.0]	1 [1.0]	
Inflammation, Acute	2 [3.0]	1 [2.0]		
Inflammation, Chronic	3 [1.0]	7 [1.0]	8 [1.0]	
Testes	(50)	(50)	(50)	(49)
Abnormal Residual Body		1 [1.0]	1 [1.0]	1 [1.0]
Angiectasis				1 [4.0]
Giant Cell	2 [1.0]		4 [1.0]	2 [1.0]
Germinal Epithelium, Atrophy	11 [1.5]	8 [1.4]	20 [1.4]	13 [1.5]

a - Number of animals examined microscopically at site and number of animals with lesion

b-Average severity grade(1-minimal;2-mild;3-moderate;4-marked)

Test Type: CHRONIC

Pentabromodiphenyl oxide (technical) (DE 71)

Time Report Requested: 08:48:44

Route: GAVAGE

CAS Number: 32534-81-9

First Dose M/F: 02/25/08 / 02/25/08

Species/Strain: MICE/B6C3F1

Lab: SRI

B6C3F1 MICE MALE	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
HEMATOPOIETIC SYSTEM				
Bone Marrow	(50)	(50)	(50)	(50)
Myeloid Cell, Hyperplasia	2 [1.5]			
Lymph Node	(5)	(4)	(4)	(1)
Hyperplasia, Lymphoid	1 [2.0]			
Pigmentation	2 [2.5]		2 [3.0]	
Iliac, Hyperplasia, Lymphoid		1 [4.0]		
Inguinal, Hyperplasia, Lymphoid				1 [2.0]
Inguinal, Pigmentation			1 [3.0]	
Lymph Node, Mandibular	(50)	(49)	(49)	(46)
Atrophy	1 [2.0]		1 [2.0]	
Hemorrhage	2 [1.5]	3 [2.7]		
Hyperplasia, Lymphoid		1 [1.0]		
Hyperplasia, Plasma Cell	1 [2.0]			
Infiltration Cellular, Polymorphonuclear	1 [2.0]	1 [3.0]		
Necrosis, Lymphoid	1 [2.0]			
Pigmentation	45 [1.5]	48 [1.4]	46 [1.5]	44 [1.7]
Lymph Node, Mesenteric	(49)	(47)	(46)	(47)
Angiectasis			1 [3.0]	
Atrophy				3 [2.0]
Congestion	1 [4.0]		3 [1.3]	
Ectasia	1 [3.0]	1 [3.0]	1 [2.0]	2 [2.0]
Hematopoietic Cell Proliferation	1 [2.0]		1 [2.0]	
Hemorrhage	3 [2.7]	7 [2.1]	7 [2.0]	8 [2.3]
Hyperplasia, Lymphoid	1 [3.0]	1 [2.0]	1 [2.0]	1 [2.0]
Hyperplasia, Plasma Cell			1 [2.0]	
Infiltration Cellular, Polymorphonuclear	1 [2.0]	1 [2.0]		1 [2.0]
Necrosis, Lymphoid		1 [2.0]		
Pigmentation	1 [1.0]		2 [1.5]	4 [1.5]
Spleen	(50)	(47)	(47)	(47)
Atrophy	1 [3.0]			
Hematopoietic Cell Proliferation	14 [2.1]	10 [2.2]	13 [2.2]	25 [1.8]
Infiltration Cellular, Eosinophil				1 [3.0]

a - Number of animals examined microscopically at site and number of animals with lesion

b-Average severity grade(1-minimal;2-mild;3-moderate;4-marked)

Test Type: CHRONIC

Pentabromodiphenyl oxide (technical) (DE 71)

Time Report Requested: 08:48:44

Route: GAVAGE

CAS Number: 32534-81-9

First Dose M/F: 02/25/08 / 02/25/08

Species/Strain: MICE/B6C3F1

Lab: SRI

B6C3F1 MICE MALE	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Pigmentation	13 [1.8]	12 [1.4]	2 [1.5]	2 [1.0]
Capsule, Fibrosis, Focal		1 [2.0]		
Capsule, Inflammation, Granulomatous, Focal		1 [2.0]		
Lymphoid Follicle, Atrophy	1 [2.0]	2 [2.5]	3 [2.3]	4 [2.8]
Lymphoid Follicle, Hyperplasia	11 [1.8]	7 [1.4]	9 [1.4]	5 [1.8]
Thymus	(40)	(41)	(40)	(39)
Atrophy	26 [2.2]	28 [2.6]	23 [2.7]	23 [3.1]
Cyst	14 [2.0]	12 [2.0]	13 [2.0]	3 [2.0]
Hemorrhage				1 [2.0]
Hyperplasia, Lymphoid	1 [1.0]	2 [1.0]	3 [1.3]	1 [1.0]
Infiltration Cellular, Histiocyte			1 [1.0]	1 [2.0]
Inflammation, Granulomatous, Focal			1 [2.0]	
Necrosis, Lymphoid		6 [2.3]	3 [2.7]	3 [2.7]

INTEGUMENTARY SYSTEM

Mammary Gland	(2)	(2)	(1)	(4)
Skin	(50)	(50)	(50)	(50)
Cyst Epithelial Inclusion			1	
Fibrosis		1 [2.0]		1 [2.0]
Fibrosis, Focal			1 [3.0]	
Foreign Body				1 [3.0]
Hemorrhage				1 [2.0]
Hyperkeratosis	1 [4.0]	3 [2.7]		1 [1.0]
Inflammation, Acute	2 [1.5]	1 [2.0]	2 [2.0]	1 [1.0]
Inflammation, Chronic	2 [2.0]	3 [1.3]		2 [1.0]
Inflammation, Chronic Active	1 [1.0]	1 [3.0]		1 [2.0]
Mineralization			2 [2.0]	
Thrombosis				1 [2.0]
Ulcer	2 [4.0]	1 [4.0]	1 [4.0]	1 [4.0]
Epidermis, Hyperplasia	1 [2.0]	1 [2.0]		
Epidermis, Tail, Hyperplasia				2 [1.0]
Lip, Inflammation, Acute	2 [1.0]	1 [1.0]		
Prepuce, Inflammation, Acute			2 [3.0]	
Subcutaneous Tissue, Angiectasis, Focal		1 [2.0]		

a - Number of animals examined microscopically at site and number of animals with lesion

b-Average severity grade(1-minimal;2-mild;3-moderate;4-marked)

Test Type: CHRONIC

Pentabromodiphenyl oxide (technical) (DE 71)

Time Report Requested: 08:48:44

Route: GAVAGE

CAS Number: 32534-81-9

First Dose M/F: 02/25/08 / 02/25/08

Species/Strain: MICE/B6C3F1

Lab: SRI

B6C3F1 MICE MALE	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Subcutaneous Tissue, Cyst			1 [2.0]	
Subcutaneous Tissue, Inflammation, Chronic	1 [1.0]			
Subcutaneous Tissue, Necrosis	1 [2.0]			

MUSCULOSKELETAL SYSTEM

Bone	(49)	(50)	(50)	(49)
Fibro-Osseous Lesion	2 [1.0]	1 [1.0]		
Tail, Callus		2 [1.0]		1 [2.0]
Tail, Developmental Malformation	1	3		
Vertebra, Callus	2 [2.5]			
Skeletal Muscle	(2)	(2)	(0)	(0)
Fibrosis	2 [3.5]			
Hemorrhage	2 [3.5]			
Inflammation, Chronic	2 [2.5]			
Regeneration	1 [2.0]			

NERVOUS SYSTEM

Brain	(50)	(50)	(50)	(50)
Cyst Epithelial Inclusion				1 [4.0]
Hemorrhage	6 [1.0]	2 [1.0]	2 [1.0]	5 [1.2]
Infiltration Cellular, Mononuclear Cell		2 [1.0]		
Inflammation, Acute				1 [1.0]
Metaplasia, Osseous		1 [1.0]		
Necrosis			1 [2.0]	
Meninges, Inflammation, Acute		1 [2.0]		
Meninges, Inflammation, Chronic	1 [1.0]			
Meninges, Thrombosis		1 [2.0]		
Peripheral Nerve	(2)	(1)	(1)	(0)
Degeneration	2 [3.0]	1 [1.0]	1 [1.0]	
Hemorrhage	1 [2.0]			
Spinal Cord	(1)	(1)	(1)	(0)
Degeneration			1 [2.0]	
Hemorrhage			1 [1.0]	

a - Number of animals examined microscopically at site and number of animals with lesion

b-Average severity grade(1-minimal;2-mild;3-moderate;4-marked)

Test Type: CHRONIC

Pentabromodiphenyl oxide (technical) (DE 71)

Time Report Requested: 08:48:44

Route: GAVAGE

CAS Number: 32534-81-9

First Dose M/F: 02/25/08 / 02/25/08

Species/Strain: MICE/B6C3F1

Lab: SRI

B6C3F1 MICE MALE	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
------------------	---------	---------	----------	-----------

RESPIRATORY SYSTEM

Lung	(50)	(50)	(50)	(50)
Congestion	1			2 [2.5]
Fibrosis			1 [1.0]	
Foreign Body				1 [3.0]
Hemorrhage	10 [1.9]	6 [2.0]	6 [1.7]	3 [1.7]
Hyperplasia				1 [1.0]
Infiltration Cellular, Histiocyte	8 [2.8]	11 [1.8]	5 [2.0]	1 [1.0]
Inflammation, Acute	2 [1.0]	1 [1.0]		1 [2.0]
Inflammation, Chronic	1 [2.0]			1 [1.0]
Metaplasia, Osseous				1 [1.0]
Mineralization	1 [1.0]	2 [1.0]	3 [1.3]	2 [1.0]
Thrombosis	3 [2.0]			
Alveolar Epithelium, Hyperplasia	2 [2.5]	6 [3.2]	1 [2.0]	
Alveolar Epithelium, Hypertrophy				1 [1.0]
Alveolus, Infiltration Cellular, Histiocyte			1 [1.0]	
Nose	(50)	(48)	(50)	(50)
Foreign Body	4 [1.3]	7 [1.4]	7 [1.3]	5 [2.0]
Fungus	1		2	
Hemorrhage			1 [2.0]	
Inflammation, Acute	9 [1.6]	12 [1.6]	19 [1.4]	6 [1.3]
Mineralization	2 [1.0]	2 [1.0]	2 [1.5]	
Glands, Fibrosis	1 [2.0]			
Pleura	(0)	(1)	(0)	(0)
Trachea	(47)	(48)	(49)	(47)
Hemorrhage		1 [2.0]		

SPECIAL SENSES SYSTEM

Eye	(49)	(47)	(47)	(46)
Atrophy	1 [4.0]			
Cataract			1 [1.0]	
Anterior Chamber, Edema	1 [2.0]			

a - Number of animals examined microscopically at site and number of animals with lesion

b-Average severity grade(1-minimal;2-mild;3-moderate;4-marked)

Test Type: CHRONIC

Pentabromodiphenyl oxide (technical) (DE 71)

Time Report Requested: 08:48:44

Route: GAVAGE

CAS Number: 32534-81-9

First Dose M/F: 02/25/08 / 02/25/08

Species/Strain: MICE/B6C3F1

Lab: SRI

B6C3F1 MICE MALE	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Anterior Chamber, Infiltration Cellular, Polymorphonuclear	1 [2.0]			
Anterior Chamber, Necrosis	1 [2.0]			
Cornea, Fibrosis	1 [2.0]			
Cornea, Inflammation	1 [2.0]			
Cornea, Inflammation, Acute	1 [2.0]		1 [3.0]	
Cornea, Inflammation, Chronic Active	1 [1.0]	1 [2.0]		
Cornea, Necrosis	1 [2.0]		1 [3.0]	
Cornea, Epithelium, Hyperplasia	1 [1.0]			
Nerve, Degeneration	1 [2.0]			
Nerve, Inflammation, Acute	1 [1.0]			
Retrobulbar, Inflammation, Acute			1 [1.0]	
Harderian Gland	(50)	(49)	(50)	(50)
Atrophy	1 [4.0]			
Fibrosis	1 [4.0]			
Hemorrhage	1 [2.0]			
Hyperplasia	1 [2.0]	2 [4.0]	1 [3.0]	
Hyperplasia, Focal	1 [1.0]			
Inflammation, Acute	1 [2.0]			
Inflammation, Chronic	1 [1.0]			
Necrosis	1 [4.0]			
Zymbal's Gland	(1)	(0)	(0)	(0)

URINARY SYSTEM

Kidney	(50)	(50)	(49)	(50)
Casts Protein		1 [2.0]		
Congestion	1 [3.0]			
Hydronephrosis		1 [2.0]		
Hyperplasia, Lymphoid		1 [2.0]	1 [1.0]	
Infarct	2 [2.0]	1 [2.0]	5 [2.4]	
Infarct, Multiple	1 [3.0]			
Infiltration Cellular, Mononuclear Cell	35 [1.1]	41 [1.0]	39 [1.0]	26 [1.0]
Inflammation			1 [4.0]	
Inflammation, Acute	1 [2.0]	1 [3.0]		

a - Number of animals examined microscopically at site and number of animals with lesion

b-Average severity grade(1-minimal;2-mild;3-moderate;4-marked)

Test Type: CHRONIC

Pentabromodiphenyl oxide (technical) (DE 71)

Time Report Requested: 08:48:44

Route: GAVAGE

CAS Number: 32534-81-9

First Dose M/F: 02/25/08 / 02/25/08

Species/Strain: MICE/B6C3F1

Lab: SRI

B6C3F1 MICE MALE	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Metaplasia, Osseous	2 [1.0]	2 [1.5]	1 [1.0]	
Mineralization	36 [1.1]	32 [1.2]	24 [1.0]	6 [1.0]
Nephropathy	38 [1.5]	45 [1.7]	37 [1.3]	9 [1.0]
Artery, Perirenal Tissue, Inflammation	1 [2.0]			
Interstitial, Inflammation	1 [3.0]			
Interstitial, Inflammation, Chronic	2 [2.5]	1 [2.0]	1 [1.0]	
Papilla, Inflammation, Acute	1 [1.0]	2 [1.5]		
Papilla, Necrosis	4 [1.3]	6 [2.7]	2 [1.0]	
Papilla, Pelvis, Inflammation, Acute			1 [3.0]	
Papilla, Renal Tubule, Necrosis		1 [2.0]		
Pelvis, Inflammation, Acute	1 [2.0]			
Pelvis, Inflammation, Chronic	1 [2.0]			
Renal Tubule, Cyst	1	2	1	
Renal Tubule, Cyst, Multiple	1			
Renal Tubule, Degeneration	3 [2.3]		2 [2.5]	
Renal Tubule, Dilatation	14 [1.1]	14 [1.1]	15 [1.0]	9 [1.0]
Renal Tubule, Hyperplasia		1 [1.0]		
Renal Tubule, Pigmentation	1 [4.0]		3 [2.3]	
Transitional Epithelium, Hyperplasia	1 [1.0]			
Urethra	(0)	(4)	(3)	(0)
Angiectasis		1 [4.0]	1 [4.0]	
Hemorrhage			1 [1.0]	
Inflammation, Acute		2 [2.0]	2 [2.5]	
Necrosis		1 [1.0]	1 [2.0]	
Bulbourethral Gland, Cyst		1 [4.0]		
Bulbourethral Gland, Hemorrhage			1 [2.0]	
Bulbourethral Gland, Inflammation		1 [2.0]		
Bulbourethral Gland, Necrosis		2 [3.0]	1 [4.0]	
Urinary Bladder	(50)	(49)	(48)	(48)
Fibrosis		1 [2.0]		
Hemorrhage	2 [2.0]	1 [2.0]	1 [2.0]	
Hyperplasia, Lymphoid			1 [1.0]	
Inflammation, Acute	2 [1.5]	1 [2.0]	1 [1.0]	
Inflammation, Chronic Active		1 [1.0]	1 [2.0]	
Necrosis	1 [1.0]	3 [1.7]	3 [1.0]	

a - Number of animals examined microscopically at site and number of animals with lesion

b-Average severity grade(1-minimal;2-mild;3-moderate;4-marked)

Experiment Number: 20209 - 04

**P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH
AVERAGE SEVERITY GRADES[b]**

Date Report Requested: 09/10/2014

Test Type: CHRONIC

Pentabromodiphenyl oxide (technical) (DE 71)

Time Report Requested: 08:48:44

Route: GAVAGE

CAS Number: 32534-81-9

First Dose M/F: 02/25/08 / 02/25/08

Species/Strain: MICE/B6C3F1

Lab: SRI

B6C3F1 MICE MALE

0 MG/KG

3 MG/KG

30 MG/KG

100 MG/KG

*** END OF MALE ***

a - Number of animals examined microscopically at site and number of animals with lesion
b-Average severity grade(1-minimal;2-mild;3-moderate;4-marked)

Test Type: CHRONIC

Pentabromodiphenyl oxide (technical) (DE 71)

Time Report Requested: 08:48:44

Route: GAVAGE

CAS Number: 32534-81-9

First Dose M/F: 02/25/08 / 02/25/08

Species/Strain: MICE/B6C3F1

Lab: SRI

B6C3F1 MICE FEMALE	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
--------------------	---------	---------	----------	-----------

Disposition Summary

Animals Initially In Study	50	50	50	50
Early Deaths				
Accidentally Killed	1			
Dosing Accident			1	
Moribund Sacrifice	10	10	9	46
Natural Death	6	5	3	4
Survivors				
Terminal Sacrifice	33	35	37	
Animals Examined Microscopically	50	50	50	50

ALIMENTARY SYSTEM

Esophagus	(50)	(50)	(50)	(49)
Foreign Body			1 [4.0]	
Inflammation, Granulomatous				1 [2.0]
Inflammation, Acute			1 [2.0]	
Inflammation, Chronic		1 [1.0]		
Necrosis	1 [1.0]			
Muscularis, Degeneration	1 [2.0]	1 [2.0]	2 [1.5]	3 [1.7]
Gallbladder	(44)	(44)	(47)	(45)
Intestine Large, Cecum	(46)	(45)	(47)	(47)
Intestine Large, Colon	(47)	(45)	(47)	(47)
Intestine Large, Rectum	(47)	(46)	(47)	(47)
Diverticulum			1 [4.0]	
Edema		1 [3.0]		
Intestine Small, Duodenum	(46)	(45)	(47)	(47)
Intestine Small, Ileum	(46)	(45)	(47)	(47)
Hyperplasia, Lymphoid	1 [2.0]			
Ulcer	1 [4.0]			
Intestine Small, Jejunum	(46)	(45)	(47)	(47)
Inflammation, Acute			1 [2.0]	
Liver	(50)	(49)	(50)	(49)
Basophilic Focus	1	1	1	2
Clear Cell Focus		3	2	2

a - Number of animals examined microscopically at site and number of animals with lesion

b-Average severity grade(1-minimal;2-mild;3-moderate;4-marked)

Test Type: CHRONIC

Pentabromodiphenyl oxide (technical) (DE 71)

Time Report Requested: 08:48:44

Route: GAVAGE

CAS Number: 32534-81-9

First Dose M/F: 02/25/08 / 02/25/08

Species/Strain: MICE/B6C3F1

Lab: SRI

B6C3F1 MICE FEMALE	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Eosinophilic Focus	3	1	15	8
Eosinophilic Focus, Multiple		1	1	7
Fatty Change	18 [1.4]	18 [1.4]	39 [1.6]	20 [1.2]
Fibrosis	1 [4.0]	1 [2.0]		
Hematopoietic Cell Proliferation	13 [1.1]	15 [1.1]	8 [1.1]	13 [1.0]
Hemorrhage	4 [1.5]	1 [2.0]	4 [1.3]	5 [1.6]
Inflammation, Acute				1 [1.0]
Inflammation, Chronic	32 [1.2]	33 [1.3]	34 [1.2]	32 [1.2]
Mixed Cell Focus		2		1
Necrosis, Focal	1 [1.0]	1 [2.0]	4 [1.8]	3 [2.7]
Tension Lipidosis	3 [1.7]	2 [2.0]	2 [1.5]	
Centrilobular, Mineralization			1 [2.0]	
Centrilobular, Necrosis			2 [2.5]	
Centrilobular, Hepatocyte, Hypertrophy		7 [1.0]	45 [2.2]	47 [2.9]
Hepatocyte, Cytoplasmic Alteration			1 [3.0]	
Kupffer Cell, Pigmentation	3 [1.3]	10 [1.1]	24 [1.2]	27 [1.4]
Midzonal, Necrosis			1 [4.0]	
Mesentery	(11)	(26)	(12)	(5)
Accessory Spleen		1		
Cyst		1		
Inflammation, Chronic		1 [2.0]		
Inflammation, Chronic Active	1 [3.0]			
Mineralization		1 [2.0]		
Fat, Necrosis	10 [2.2]	22 [2.4]	12 [2.0]	3 [2.3]
Oral Mucosa	(0)	(1)	(0)	(0)
Pancreas	(50)	(48)	(50)	(50)
Atrophy	6 [1.8]	8 [1.9]	5 [2.2]	
Cyst	1 [2.0]	3 [2.3]	3 [2.7]	
Fibrosis		1 [2.0]	1 [3.0]	
Inflammation, Chronic	29 [1.2]	31 [1.2]	31 [1.3]	22 [1.2]
Inflammation, Chronic Active		1 [3.0]		
Mineralization, Chronic			1 [1.0]	
Necrosis	1 [2.0]	1 [2.0]		1 [2.0]
Duct, Cyst				1
Salivary Glands	(50)	(50)	(50)	(48)
Atrophy	1 [2.0]		1 [3.0]	

a - Number of animals examined microscopically at site and number of animals with lesion

b-Average severity grade(1-minimal;2-mild;3-moderate;4-marked)

Test Type: CHRONIC

Pentabromodiphenyl oxide (technical) (DE 71)

Time Report Requested: 08:48:44

Route: GAVAGE

CAS Number: 32534-81-9

First Dose M/F: 02/25/08 / 02/25/08

Species/Strain: MICE/B6C3F1

Lab: SRI

B6C3F1 MICE FEMALE	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Infiltration Cellular, Mononuclear Cell	32 [1.2]	37 [1.2]	30 [1.0]	26 [1.1]
Mineralization	1 [1.0]	5 [1.0]	5 [1.4]	1 [1.0]
Necrosis	1 [4.0]			
Stomach, Forestomach	(50)	(50)	(50)	(49)
Angiectasis, Focal				1 [3.0]
Cyst	1		1	
Edema	1 [2.0]			
Erosion		1 [1.0]	2 [1.0]	3 [1.7]
Hemorrhage	1 [3.0]			
Infiltration Cellular, Mast Cell			1 [1.0]	
Inflammation	5 [1.8]	3 [1.7]	5 [1.2]	6 [1.5]
Inflammation, Acute				1 [2.0]
Inflammation, Chronic	2 [1.5]			
Mineralization		1 [2.0]		
Ulcer	5 [2.2]	3 [1.7]	1 [2.0]	1 [2.0]
Epithelium, Hyperplasia	9 [1.9]	5 [1.6]	6 [2.7]	16 [2.6]
Stomach, Glandular	(49)	(47)	(47)	(48)
Erosion	1 [2.0]			1 [4.0]
Inflammation, Acute	1 [1.0]	1 [1.0]	1 [3.0]	
Mineralization	5 [1.6]	6 [1.3]	6 [1.5]	1 [1.0]
Ulcer		1 [1.0]	1 [4.0]	
Epithelium, Vacuolization Cytoplasmic	1 [2.0]			
Glands, Ectasia, Focal	4 [2.3]	3 [1.7]	4 [2.3]	1 [1.0]

CARDIOVASCULAR SYSTEM

Blood Vessel	(47)	(49)	(50)	(49)
Inflammation	1 [2.0]			
Mineralization	1 [4.0]		1 [1.0]	
Heart	(50)	(50)	(50)	(49)
Cardiomyopathy	4 [1.0]	8 [1.0]	5 [1.0]	
Hemorrhage			1 [2.0]	
Inflammation, Chronic		1 [1.0]		
Mineralization	1 [1.0]	4 [1.5]	2 [2.0]	1 [1.0]
Necrosis, Multifocal			1 [2.0]	

a - Number of animals examined microscopically at site and number of animals with lesion

b-Average severity grade(1-minimal;2-mild;3-moderate;4-marked)

Test Type: CHRONIC

Pentabromodiphenyl oxide (technical) (DE 71)

Time Report Requested: 08:48:44

Route: GAVAGE

CAS Number: 32534-81-9

First Dose M/F: 02/25/08 / 02/25/08

Species/Strain: MICE/B6C3F1

Lab: SRI

B6C3F1 MICE FEMALE	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Thrombosis			1 [3.0]	
Valve, Thrombosis	1 [1.0]			

ENDOCRINE SYSTEM

Adrenal Cortex	(50)	(50)	(49)	(47)
Accessory Adrenal Cortical Nodule	5 [2.0]	5 [2.0]	1 [2.0]	3 [1.0]
Degeneration, Fatty	3 [1.7]	2 [2.5]	3 [1.7]	
Hematopoietic Cell Proliferation		2 [2.0]	2 [2.5]	1 [1.0]
Hemorrhage	1 [2.0]			2 [3.5]
Hyperplasia	1 [2.0]		4 [2.0]	
Hyperplasia, Focal		1 [3.0]		
Hypertrophy, Focal	7 [1.4]	4 [1.3]	9 [1.4]	2 [1.5]
Hypertrophy, Diffuse			4 [1.0]	8 [1.4]
Capsule, Cyst				1
Capsule, Hyperplasia	49 [2.5]	50 [2.6]	47 [2.4]	47 [2.4]
Adrenal Medulla	(49)	(50)	(48)	(48)
Hyperplasia	1 [1.0]		1 [1.0]	
Pigmentation		1 [2.0]		
Islets, Pancreatic	(50)	(48)	(50)	(50)
Hyperplasia	3 [1.0]	3 [1.0]	2 [1.0]	1 [1.0]
Parathyroid Gland	(44)	(48)	(47)	(47)
Cyst	2 [2.0]	1 [2.0]	1 [2.0]	
Hyperplasia			1 [1.0]	
Pituitary Gland	(50)	(47)	(46)	(45)
Pars Distalis, Angiectasis		1 [2.0]	1 [2.0]	
Pars Distalis, Cyst	2 [2.0]		1 [2.0]	
Pars Distalis, Hyperplasia	9 [1.7]	13 [1.9]	13 [1.8]	10 [2.0]
Rathke's Cleft, Cyst	1 [2.0]			1 [2.0]
Thyroid Gland	(50)	(49)	(48)	(47)
Infiltration Cellular, Mononuclear Cell		1 [2.0]		
Inflammation, Chronic	1 [1.0]	1 [1.0]		
Follicle, Cyst	2	1		
Follicle, Degeneration	34 [1.9]	28 [2.0]	26 [1.5]	11 [1.3]
Follicle, Degeneration, Focal		1 [1.0]		

a - Number of animals examined microscopically at site and number of animals with lesion

b-Average severity grade(1-minimal;2-mild;3-moderate;4-marked)

Test Type: CHRONIC

Pentabromodiphenyl oxide (technical) (DE 71)

Time Report Requested: 08:48:44

Route: GAVAGE

CAS Number: 32534-81-9

First Dose M/F: 02/25/08 / 02/25/08

Species/Strain: MICE/B6C3F1

Lab: SRI

B6C3F1 MICE FEMALE	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Follicle, Hypertrophy	24 [1.3]	31 [1.5]	37 [1.5]	42 [2.4]
Follicular Cell, Hyperplasia				1 [1.0]

GENERAL BODY SYSTEM

Peritoneum	(0)	(0)	(0)	(1)
Tissue NOS	(1)	(2)	(0)	(1)
Abscess, Chronic				1 [4.0]
Fibrosis		1 [3.0]		
Foreign Body				1
Inflammation, Chronic		1 [2.0]		
Mineralization		1 [2.0]		
Fat, Fibrosis		1 [4.0]		
Fat, Inflammation, Chronic Active		1 [3.0]		
Fat, Necrosis		1 [2.0]		

GENITAL SYSTEM

Clitoral Gland	(49)	(49)	(50)	(50)
Cyst	1 [2.0]			
Inflammation, Acute	1 [4.0]			
Inflammation, Chronic Active	5 [1.0]	13 [1.1]	8 [1.1]	18 [1.2]
Ovary	(48)	(49)	(50)	(48)
Abscess, Chronic Active	1 [4.0]			
Angiectasis	1 [2.0]		1 [4.0]	
Atrophy				1 [1.0]
Cyst	13 [2.0]	13 [2.0]	6 [2.0]	7 [2.0]
Thrombosis			1 [4.0]	
Uterus	(50)	(50)	(50)	(49)
Angiectasis	1 [2.0]			
Cyst	2 [2.0]			
Edema	1 [3.0]			
Hemorrhage	1 [4.0]	2 [2.0]		
Hyperplasia, Cystic	45 [2.5]	47 [2.2]	46 [2.8]	43 [2.7]
Inflammation, Histiocytic	1 [3.0]			

a - Number of animals examined microscopically at site and number of animals with lesion

b-Average severity grade(1-minimal;2-mild;3-moderate;4-marked)

Test Type: CHRONIC

Pentabromodiphenyl oxide (technical) (DE 71)

Time Report Requested: 08:48:44

Route: GAVAGE

CAS Number: 32534-81-9

First Dose M/F: 02/25/08 / 02/25/08

Species/Strain: MICE/B6C3F1

Lab: SRI

B6C3F1 MICE FEMALE	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Inflammation, Acute	1 [4.0]		1 [4.0]	
Necrosis	1 [4.0]		1 [4.0]	
Thrombosis	1 [2.0]			
Serosa, Cyst				1
Vagina	(0)	(1)	(0)	(0)
HEMATOPOIETIC SYSTEM				
Bone Marrow	(49)	(50)	(50)	(49)
Infiltration Cellular, Histiocyte	1 [2.0]			
Myeloid Cell, Hyperplasia	1 [2.0]	3 [2.7]	1 [4.0]	
Lymph Node	(9)	(17)	(12)	(4)
Ectasia	3 [4.0]	6 [3.7]	4 [3.5]	
Hemorrhage	3 [2.7]	5 [4.0]	3 [3.0]	
Hyperplasia, Lymphoid		2 [2.0]		1 [2.0]
Pigmentation	3 [3.0]	5 [2.6]	5 [3.0]	
Iliac, Ectasia			1 [4.0]	
Iliac, Hemorrhage		1 [4.0]	1 [4.0]	
Iliac, Hyperplasia, Lymphoid	1 [4.0]		1 [4.0]	
Iliac, Hyperplasia, Plasma Cell			1 [3.0]	
Lumbar, Pigmentation			1 [3.0]	
Pancreatic, Hyperplasia, Lymphoid		1 [3.0]		
Renal, Hematopoietic Cell Proliferation		1 [2.0]		
Renal, Hyperplasia, Lymphoid			1 [1.0]	
Renal, Pigmentation		1 [2.0]	1 [2.0]	
Lymph Node, Mandibular	(48)	(50)	(50)	(45)
Atrophy	1 [4.0]			
Ectasia	1 [2.0]			
Fibrosis	1 [2.0]			
Hematopoietic Cell Proliferation				1 [1.0]
Hemorrhage				1 [1.0]
Hyperplasia, Lymphoid	3 [2.3]	3 [2.0]	2 [2.5]	
Hyperplasia, Plasma Cell	1 [1.0]	1 [2.0]		
Infiltration Cellular, Mast Cell			1 [3.0]	
Inflammation, Chronic Active	1 [2.0]			

a - Number of animals examined microscopically at site and number of animals with lesion

b-Average severity grade(1-minimal;2-mild;3-moderate;4-marked)

Test Type: CHRONIC

Pentabromodiphenyl oxide (technical) (DE 71)

Time Report Requested: 08:48:44

Route: GAVAGE

CAS Number: 32534-81-9

First Dose M/F: 02/25/08 / 02/25/08

Species/Strain: MICE/B6C3F1

Lab: SRI

B6C3F1 MICE FEMALE	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Pigmentation	36 [2.1]	39 [2.1]	41 [2.0]	38 [1.9]
Lymph Node, Mesenteric	(48)	(45)	(49)	(48)
Atrophy	1 [2.0]		1 [3.0]	1 [2.0]
Ectasia		1 [2.0]	3 [2.7]	
Hemorrhage		2 [1.5]		
Hyperplasia, Lymphoid	1 [3.0]	1 [2.0]	1 [2.0]	
Hyperplasia, Plasma Cell	1 [3.0]			
Necrosis, Lymphoid				2 [1.0]
Pigmentation				2 [1.0]
Spleen	(50)	(47)	(48)	(48)
Accessory Spleen		1		
Atrophy	1 [2.0]			
Hematopoietic Cell Proliferation	15 [1.9]	10 [2.9]	11 [2.8]	24 [2.3]
Necrosis	1 [4.0]			
Pigmentation	35 [1.6]	26 [1.8]	28 [1.9]	31 [1.4]
Lymphoid Follicle, Atrophy	2 [2.0]	1 [1.0]	3 [1.7]	1 [1.0]
Lymphoid Follicle, Hyperplasia	12 [1.7]	20 [1.7]	7 [2.3]	21 [1.6]
Lymphoid Follicle, Hyperplasia, Plasma Cell	1 [2.0]			
Lymphoid Follicle, Hyperplasia, Focal	2 [2.0]			
Thymus	(48)	(45)	(46)	(46)
Atrophy	25 [2.2]	22 [1.7]	26 [1.6]	13 [2.6]
Cyst	8 [2.0]	6 [2.0]	6 [2.0]	2 [2.0]
Hyperplasia, Lymphoid	16 [1.8]	16 [1.9]	9 [1.1]	10 [1.5]
Mineralization	1 [1.0]			
Necrosis, Lymphoid	2 [1.5]	1 [1.0]	1 [1.0]	

INTEGUMENTARY SYSTEM

Mammary Gland	(50)	(50)	(50)	(50)
Galactocele	30 [1.3]	28 [1.4]	32 [1.3]	31 [1.6]
Hyperplasia	3 [1.7]		5 [1.4]	
Inflammation, Chronic	1 [1.0]	2 [1.0]	3 [1.0]	1 [2.0]
Inflammation, Chronic Active			1 [1.0]	1 [2.0]
Skin	(50)	(50)	(50)	(50)
Cyst Epithelial Inclusion	2 [2.5]			

a - Number of animals examined microscopically at site and number of animals with lesion

b-Average severity grade(1-minimal;2-mild;3-moderate;4-marked)

Test Type: CHRONIC

Pentabromodiphenyl oxide (technical) (DE 71)

Time Report Requested: 08:48:44

Route: GAVAGE

CAS Number: 32534-81-9

First Dose M/F: 02/25/08 / 02/25/08

Species/Strain: MICE/B6C3F1

Lab: SRI

B6C3F1 MICE FEMALE	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Edema		2 [3.5]	1 [3.0]	
Fibrosis	1 [1.0]		2 [2.5]	
Foreign Body	1 [1.0]	1 [1.0]	1 [1.0]	
Hemorrhage	1 [2.0]	2 [2.0]		
Hyperkeratosis	1 [2.0]	1 [3.0]		
Infiltration Cellular, Mast Cell		1 [1.0]		
Inflammation, Granulomatous	1 [4.0]	1 [2.0]		
Inflammation, Acute	2 [2.0]	4 [2.8]	3 [1.7]	
Inflammation, Chronic	6 [1.0]	8 [1.1]	10 [1.1]	8 [1.1]
Inflammation, Chronic Active	2 [1.0]	2 [2.5]	3 [2.7]	2 [1.5]
Mineralization		2 [2.5]	2 [1.5]	1 [2.0]
Necrosis, Fatty, Focal				1 [2.0]
Ulcer	4 [4.0]	4 [4.0]	6 [3.7]	
Epidermis, Hyperplasia			1 [3.0]	
Epidermis, Tail, Hyperkeratosis	1 [1.0]		2 [1.5]	
Epidermis, Tail, Hyperplasia	1 [1.0]	4 [1.3]	3 [2.3]	
Hair Follicle, Atrophy, Focal				1 [2.0]
Hair Follicle, Inflammation, Chronic Active				1 [2.0]
Lip, Foreign Body		1 [2.0]		
Lip, Inflammation, Chronic	1 [1.0]	1 [2.0]		
Lip, Inflammation, Chronic Active		1 [2.0]		
Subcutaneous Tissue, Fibrosis		1 [2.0]		

MUSCULOSKELETAL SYSTEM

Bone	(49)	(50)	(50)	(50)
Fibro-Osseous Lesion	43 [1.3]	46 [1.4]	49 [1.5]	43 [1.1]
Tail, Callus	1 [1.0]		2 [2.0]	1 [2.0]
Tail, Developmental Malformation			1	
Vertebra, Callus			1 [4.0]	
Skeletal Muscle	(2)	(3)	(4)	(1)
Fibrosis			1 [3.0]	
Hemorrhage			2 [3.0]	
Inflammation, Chronic			1 [3.0]	
Mineralization			1 [2.0]	

a - Number of animals examined microscopically at site and number of animals with lesion

b-Average severity grade(1-minimal;2-mild;3-moderate;4-marked)

Test Type: CHRONIC

Pentabromodiphenyl oxide (technical) (DE 71)

Time Report Requested: 08:48:44

Route: GAVAGE

CAS Number: 32534-81-9

First Dose M/F: 02/25/08 / 02/25/08

Species/Strain: MICE/B6C3F1

Lab: SRI

B6C3F1 MICE FEMALE	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Necrosis			1 [4.0]	
Regeneration			1 [2.0]	

NERVOUS SYSTEM

Brain	(50)	(50)	(50)	(49)
Compression	1 [1.0]	2 [2.0]	1 [4.0]	
Developmental Malformation				1 [2.0]
Hemorrhage	3 [1.3]	1 [1.0]	3 [1.0]	1 [1.0]
Infiltration Cellular, Mononuclear Cell	1 [1.0]	1 [1.0]	1 [1.0]	1 [1.0]
Necrosis			1 [3.0]	
Pigmentation			1 [1.0]	
Meninges, Inflammation, Chronic	1 [1.0]			
Peripheral Nerve	(1)	(1)	(1)	(1)
Degeneration	1 [1.0]		1 [3.0]	
Sciatic, Degeneration		1 [2.0]		
Spinal Cord	(1)	(1)	(3)	(1)
Degeneration			2 [2.5]	

RESPIRATORY SYSTEM

Lung	(50)	(50)	(50)	(50)
Congestion	2 [4.0]	1 [2.0]	1 [4.0]	
Cyst			1 [2.0]	
Edema				1 [3.0]
Fibrosis	1 [1.0]			
Foreign Body			1 [2.0]	
Hemorrhage	12 [1.8]	3 [2.3]	1 [2.0]	7 [1.1]
Infiltration Cellular, Histiocyte	4 [1.3]	2 [1.5]	2 [1.5]	1 [1.0]
Inflammation, Granulomatous				1 [3.0]
Inflammation, Acute			1 [3.0]	
Metaplasia, Osseous	2 [1.0]			2 [1.0]
Mineralization	3 [1.0]	2 [1.0]	3 [1.0]	
Thrombosis	1 [1.0]		1 [1.0]	1 [1.0]
Alveolar Epithelium, Hyperplasia			1 [3.0]	

a - Number of animals examined microscopically at site and number of animals with lesion

b-Average severity grade(1-minimal;2-mild;3-moderate;4-marked)

Test Type: CHRONIC

Pentabromodiphenyl oxide (technical) (DE 71)

Time Report Requested: 08:48:44

Route: GAVAGE

CAS Number: 32534-81-9

First Dose M/F: 02/25/08 / 02/25/08

Species/Strain: MICE/B6C3F1

Lab: SRI

B6C3F1 MICE FEMALE	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Alveolus, Infiltration Cellular, Histiocyte				1 [1.0]
Nose	(50)	(50)	(50)	(48)
Foreign Body	4	3	3 [1.0]	3 [1.5]
Inflammation, Acute	6 [1.5]	6 [1.3]	4 [1.5]	10 [1.6]
Mineralization				1 [2.0]
Pleura	(0)	(0)	(1)	(0)
Inflammation, Suppurative			1 [4.0]	
Trachea	(50)	(50)	(50)	(47)

SPECIAL SENSES SYSTEM

Eye	(47)	(45)	(47)	(48)
Atrophy		1 [4.0]		
Cornea, Inflammation, Acute			1 [1.0]	
Harderian Gland	(50)	(49)	(50)	(49)
Hyperplasia	1 [2.0]	2 [2.5]	2 [3.5]	1 [1.0]
Inflammation, Chronic		1 [1.0]		

URINARY SYSTEM

Kidney	(50)	(50)	(49)	(48)
Infarct			1 [2.0]	1 [2.0]
Infiltration Cellular, Mononuclear Cell	38 [1.1]	44 [1.1]	43 [1.0]	45 [1.0]
Metaplasia, Osseous			1 [1.0]	1 [1.0]
Mineralization	7 [1.1]	5 [1.0]	5 [1.0]	1 [1.0]
Nephropathy	14 [1.3]	9 [1.2]	9 [1.0]	3 [1.0]
Artery, Inflammation, Chronic	1 [2.0]			
Interstitial, Inflammation, Chronic	1 [2.0]			2 [1.0]
Papilla, Necrosis		2 [2.0]		
Pelvis, Inflammation, Chronic				1 [1.0]
Renal Tubule, Accumulation, Hyaline Droplet	2 [2.5]	1 [3.0]		1 [2.0]
Renal Tubule, Atrophy		1 [1.0]	1 [2.0]	
Renal Tubule, Cyst				1
Renal Tubule, Degeneration		1 [1.0]	1 [3.0]	
Renal Tubule, Dilatation	31 [1.0]	23 [1.0]	34 [1.0]	43 [1.1]

a - Number of animals examined microscopically at site and number of animals with lesion

b-Average severity grade(1-minimal;2-mild;3-moderate;4-marked)

Experiment Number: 20209 - 04

**P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH
AVERAGE SEVERITY GRADES[b]**

Date Report Requested: 09/10/2014

Test Type: CHRONIC

Pentabromodiphenyl oxide (technical) (DE 71)

Time Report Requested: 08:48:44

Route: GAVAGE

CAS Number: 32534-81-9

First Dose M/F: 02/25/08 / 02/25/08

Species/Strain: MICE/B6C3F1

Lab: SRI

B6C3F1 MICE FEMALE	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Renal Tubule, Necrosis			1 [3.0]	
Renal Tubule, Regeneration			1 [2.0]	
Renal Tubule, Vacuolization Cytoplasmic			1 [2.0]	
Urinary Bladder	(49)	(50)	(49)	(48)
Hyperplasia, Lymphoid	1 [2.0]			

*** END OF REPORT ***

a - Number of animals examined microscopically at site and number of animals with lesion

b-Average severity grade(1-minimal;2-mild;3-moderate;4-marked)